Date: 2013-04-30
Type of information: Collaboration agreement
Compound: recombinant Protective Antigen (rPA) from Bacillus anthracis
Company: Glide Pharma (UK) Pfenex (Australia)
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease: anthrax
Details: * On April 30, 2013, Glide Pharma has announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pf?nex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector). This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.
The Pfenex project has been funded in whole with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201200033C. Under an existing Biomedical Advanced Research and Development Authority (BARDA) contract, Pfenex has successfully developed a novel rPA that is highly immunogenic and protective in animal studies, with a scalable production process and robust yields.
Financial terms:
Latest news:
